Lead Product(s) : Cedirogant
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Cedirogant
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cedirogant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 14, 2021
Lead Product(s) : Cedirogant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cedirogant
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2019
Lead Product(s) : Cedirogant
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cedirogant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Termination
Inventiva Provides An Update On The Development Of Cedirogant By AbbVie
Details : Cedirogant (ABBV-157) is an orally available retinoic acid-related orphan receptor gamma (RORγ) inverse-agonist, small molecule for the treatment of chronic plaque psoriasis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 31, 2022
Lead Product(s) : Cedirogant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Cedirogant
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : AbbVie Inc
Deal Size : $4.3 million
Deal Type : Collaboration
Inventiva Receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation
Details : It follows the inclusion of the first patient with psoriasis in the ongoing Phase IIb clinical trial with cedirogant (ABBV-157), an oral RORγ inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 31, 2022
Lead Product(s) : Cedirogant
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : AbbVie Inc
Deal Size : $4.3 million
Deal Type : Collaboration